China pharma projects disrupted by Sino-US tensions
SHANGHAI: Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of US-China trade tensions.
China's sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer and AstraZeneca with a low-cost development model that often uses imported clinical samples, equipment, chemicals and other materials to conduct work.
Fears of delay in access to US supply chains and raised import tariffs are spurring biotech and pharmaceutical companies to avoid, pause or consider delaying the start of projects, according to three sources.
They are also discussing testing US clinical samples in the US, instead of sending them to China for further research, a move that could increase costs, and requesting additional supplies for backup, three other sources said.
The six sources who spoke to Reuters are director or executive-level employees involved in various aspects of the industry in China including research and development, manufacturing and supply chains.
All but two agreed to speak only on condition of anonymity because of concerns about effects on fundraising plans or they were not authorised to speak to media. The developments have not been reported previously.
US and Chinese officials said last week they had agreed on a framework to put a May trade truce back on track and remove China's export restrictions on rare earths, but offered little sign of a durable resolution to longstanding trade differences that have affected products ranging from semiconductors and jet engines to medical equipment and pharmaceuticals.
"What kind of long-term policy it could be, you know, what kind of tariff would it be in half a year, in one year... nobody knows. And that's the problem. That's what makes everybody worry and nervous," said Chen Gong, co-founder of NeuExcell Therapeutics, a biotech with its main operations in Suzhou.
He said the US-China trade tensions had made him more cautious about investing in a clinical trial and the company would delay its start if it did not have sufficient funding.
Reliance on US imports has come into particular focus as trade tensions escalate. In 2024, the US exported diagnostic and laboratory reagents to China valued at about US$1.4 billion and prepared culture media for the development or maintenance of microorganisms worth about US$125 million, U.N. Comtrade data showed.
In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare industry, some US-made goods including diagnostic reagents from Germany's Siemens Healthineers were exempted from raised Chinese tariffs, that company said in May.
China raised its tariffs on US imports to as much as 125 per cent though it has since reduced that to 10 per cent while it works out a more permanent trade deal.
HIGHER COSTS, DELAYS
WuXi AppTec and a Chinese biotechnology firm that was its research client agreed in May to switch US-made reagents they had been using for a Hepatitis B virus pre-clinical research project into non-U.S. versions due partly to concerns about higher costs from tariffs, a source at the client company said.
The project had been temporarily paused during the discussions, which began prior to May, the source said.
WuXi AppTec said it makes "every effort to avoid disruptions or delays in the delivery of services to customers."
Since April, at least 17 Chinese biotech and pharmaceutical clients have contacted Chinese cell culture media manufacturer JS Biosciences asking it to keep locally-made backup raw materials for production because they were concerned about cost increases or the inability to access foreign supplies, the firm's CEO Luo Shun said.
"If they have a product made by us, and we rely on the foreign raw material supply and that raw material will increase in price or is never going to come, obviously it will impact their manufacturing of those life-saving drugs. So obviously, that's their primary concern," Luo said.
Another Chinese drug research and development firm decided not to provide a quotation to a foreign pharmaceutical company interested in hiring it for protein drug manufacturing, due to delays in obtaining necessary US-made culture medium from a US subsidiary of Japan's Fujifilm, a source at the Chinese firm said.
The potential client would likely not have accepted waiting on imports of new supplies into China, which would typically take two to four months, the source said.
A Fujifilm Holdings America Corporation spokesperson said Fujifilm Biosciences, one of its life science business units, has made significant investments to build a robust global manufacturing network so that it could navigate any challenges or disruptions, without elaborating on its supply issue involving China.
STOCKPILING, US TESTING
After China announced a large rise in tariffs for US imports in April, WuXi Biologics placed a bigger-than-normal order for reagents made in the US with a supplier because it was not sure how long that policy action would continue, said a source at the supplier.
WuXi Biologics did not respond to requests for comment.
Concerns about the potential for US export restrictions led China's Innovent Biologics and multinational BeOne Medicines to discuss with Massachusetts-headquartered Thermo Fisher Scientific the prospect of not sending US clinical samples to China, said a source at the US company.
Testing US samples in-country instead of in China would be more expensive, the source said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
4 hours ago
- The Star
East African fashion life show opens in Kenya to boost textiles, apparels trade
NAIROBI, June 20 (Xinhua) -- The second edition of East Africa (Kenya) Fashion Life Show was officially opened on Friday in Nairobi, the Kenyan capital, drawing over 70 exhibitors from Kenya and China. Chinese enterprises are exhibiting textiles, packaging material, baby toys, personal care products and wigs, home decor, and gift wrappers during the expo that runs from Thursday to Saturday. Yin Maolin, Party chief of Mudan District in Heze City, east China's Shandong Province, led a high-level Chinese delegation to attend the expo that will highlight the potential of East Africa as a hub for the fashion, sustainable textile, and apparel sector. According to Yin, the fashion show offers a platform for deepening economic partnership between China and Kenya, focusing on trade in high-quality manufactured products and jointly establishing seamless supply chains. Pius Rotich, general manager for investment promotion and business development services at Kenya Investment Authority, said the government has created a conducive policy and regulatory environment to spur the growth of the textile and apparel sector. Kenya is committed to a partnership with Chinese investors in a bid to manufacture high-quality leather products for export in the African market and beyond, boosting foreign exchange earnings and job creation, said Rotich. Gao Wei, managing director of Afripeak Expo Kenya Ltd., co-organizer of the 2025 East African Fashion Show, said this year's edition had grown bigger in terms of the number of visitors and exhibitors, reaffirming dynamism in the region's textile and apparel sectors. The fashion expo, according to Gao, will run under the theme of "Inspire Friendship, Connect World," bringing together Chinese and Kenyan enterprises dealing with household accessories, cosmetics, and electronics under one roof. Gao said the expo will also create a platform for Chinese business executives to network with their Kenyan counterparts, explore two-way trade in leather products. Hundreds of Kenyan visitors thronged to the East Africa Fashion expo, with the majority acknowledging their appreciation of Chinese-made products, including wigs, cosmetics and fabrics. Waceke Mwaura, a female entrepreneur, said that she was impressed by the wig showcased by Chinese exhibitors, adding that its high quality has made it popular among local clients. Mwaura said she has been importing hair from China to supply to local retailers and beauty parlors, even as she scouts for distributorship arrangements with Chinese manufacturers. Paul Munyua, a middle-aged pedicurist, said that he visited the expo to gain insight into new beauty products in the local market imported from China that are affordable to his clients.
Barnama
5 hours ago
- Barnama
Ties Within BRICS Strengthening, Mutual Trade Growing
ST. PETERSBURG, June 20 (Bernama-RIA Novosti) -- Russian President Vladimir Putin said on Friday that ties within BRICS are strengthening and mutual trade is growing, with the trade turnover of the participating countries already exceeding US$1 trillion. "Special attention is being paid to strengthening ties within BRICS. The mutual trade turnover between our countries has already exceeded US$1 trillion and continues to grow. All of these are elements of a global growth platform. 'And they are based on the key principles of BRICS. And this is consensus, parity, and consideration of interests towards each other," Putin said at a plenary session of the 2025 St. Petersburg International Economic Forum (SPIEF), Sputnik/RIA Novosti reported.
New Straits Times
6 hours ago
- New Straits Times
Bigger mess awaits if regime change happens in Iran
ISRAEL increasingly appears eager to oust the leadership that has ruled Iran since the 1979 Islamic revolution but is taking a gamble given the Iranian opposition is divided and there is no guarantee new rulers would be any less hardline, say analysts. By striking targets other than nuclear or ballistic facilities, such as Iran's IRIB broadcaster, expectations have grown that Israel has goals beyond degrading Iranian atomic and missile capabilities and eyes removing Supreme Leader Ayatollah Ali Khamenei. But while United States President Donald Trump has warned "we know" where Khamenei "is hiding", what would follow his removal after over 3½ decades in power is shrouded in uncertainty and risk. European leaders are haunted by the aftermath of the US-led invasion of Iraq in 2003 and the Nato-led intervention in Libya in 2011. They resulted in the removal of dictators Saddam Hussein and Muammar Gaddafi but also in years of bloody mayhem in both countries. "The biggest mistake today is to seek regime change in Iran through military means because that would lead to chaos," said French President Emmanuel Macron at the end of the G7 summit in Canada. "Does anyone think that what was done in Iraq in 2003... or what was done in Libya the previous decade was a good idea? No!" he said. Analysts say ousting Khamenei and his fellow leaders risks creating a vacuum that could be filled by hardline elements in the Revolutionary Guards (IRGC) ideological force or the Iranian military. "Israel's strikes seem more focused on regime change than non-proliferation," said Nicole Grajewski, fellow at the Carnegie Endowment. "Of course, Israel is targeting ballistic missile and military related facilities but they are also targeting leadership and symbols of the regime like the IRIB. "If the regime were to fall, the hope would be for a liberal and democratic government. "However, there is a strong likelihood that other powerful entities like the IRGC could emerge as the replacement," she said. Among the highest-profile opposition figures is the US-based Reza Pahlavi, the son of ousted shah Mohammad Reza Pahlavi. He has declared that the Islamic republic is "on the verge of collapse", accusing Khamenei of "hiding underground" like a "frightened rat". Pahlavi has long called for the restoration of the warm relationship that existed between his late father and Israel, to reverse the Islamic republic's refusal to recognise the existence of Israel. Monarchists would like such a rapprochement to be termed the "Cyrus Accords" after the ancient Persian king credited with freeing the Jews from Babylon. But Pahlavi is far from enjoying universal support inside Iran or among exiles. The nationalism of supporters and his ties with Israel are divisive, especially after he refused to condemn the Israeli airstrikes on Iran. Another major organised group is the People's Mujahedin (MEK), whose leader Maryam Rajavi told the European Parliament on Wednesday: "The people of Iran want the overthrow of this regime." But the MEK is despised by other opposition factions and regarded with suspicion by some Iranians for its support of Saddam in the Iran-Iraq war. "Part of the challenge in thinking about alternatives to the Islamic Republic in case it collapses is that there is no organised, democratic alternative," said Thomas Juneau, professor at the University of Ottawa. He said while Pahlavi "who has by far the most name recognition both in and out of Iran", his supporters "tend to exaggerate his support inside the country". "The only alternative — and this is among the worrying scenarios — is a coup d'etat by the Revolutionary Guards or changing from a theocracy to a military dictatorship." Analysts also warn that a potential — and often overlooked — factor for future instability could be Iran's complex ethnic make-up. Large Kurdish, Arab, Baluch and Turkic minorities coexist alongside the Persian population. Analysts at the US-based think tank Soufan Centre said with the survival of the Iranian regime now viewed as a "strategic failure", the prospect of an "Iraq 2.0" is looming. "The post-regime-change scenario remains unpredictable and could trigger regional destabilisation on a scale greater than Iraq, with global ramifications," they said.
